Phase III
The trial met its co-primary endpoints, showing statistically significant and clinically meaningful improvements in overall survival and progression-free survival compared to standard-of-care, Bayer’s Nexavar.
Last week was busy for clinical trial news. Here’s a look.
Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.
SGM-101 is an investigational new imaging agent for fluorescence-guided surgery designed to enable surgeons to better visualize tumor tissues in real-time
Lilly picked up pegilodecakin, an immunotherapy that stimulates the body’s immune system and expands tumor-attacking T-cells, when it acquired ARMO BioSciences in June 2018 for $1.6 billion.
The primary endpoint of the trial was improving overall response rate at Day 28 with Jakafi compared to the best available therapy.
Roche announced results from its Phase III PEMPHIX trial evaluated MabThera/Rituxan (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris.
The drug met all the co-primary and key secondary endpoints related to skin clearance and itch relief compared to placebo.
As Gilead Sciences and its development partner Galapagos NV eye filing a New Drug Application with the U.S. Food and Drug Administration for its JAK inhibitor filgotinib, the companies’ hopes have been boosted by new 52-week safety data.
It was another busy week for clinical trials. Here’s a look.
PRESS RELEASES